Navigation Links
Precision Therapeutics President and CEO Sean McDonald Named Ernst & Young Entrepreneur of the Year(R) 2008 Regional Award Winner

PITTSBURGH, July 2 /PRNewswire/ -- Precision Therapeutics today announced that its President and Chief Executive Officer Sean McDonald received the Ernst & Young Entrepreneur of the Year(R) 2008 Award in the Applied Science category in the Upstate New York, Western Pennsylvania and West Virginia region. This award recognizes outstanding entrepreneurs who are building and leading dynamic growth businesses. McDonald was selected by an independent panel of judges and the award was presented at an Ernst & Young Entrepreneur of the Year gala event at the Carnegie Music Hall in Pittsburgh on Friday, June 27, 2008.

"Being named an Ernst & Young Entrepreneur of the Year is a great honor for me and my team as we work towards our goal of improving the lives of people living with cancer," said McDonald. "This is not only a win for Precision; it is also a win for the growing life science industry in the Pittsburgh region."

Sean joined Precision Therapeutics in 2001 and serves as President and CEO. Prior to joining Precision, Sean founded Automated Healthcare in 1992, developing the first robotics-based solution to hospital pharmacy management. Automated Healthcare was successfully acquired by McKesson Corporation in 1996. In addition to his current award, Sean has been recognized with a 1999 Ernst & Young Entrepreneur of the Year Award, a 1999 Carnegie Award for Excellence in Science and Technology, the Smithsonian Institution Award for heroic achievement in information technology, and the Pittsburgh Life Sciences Greenhouse 2004 PIONEER award. Sean received a BS in Engineering from the University of Pennsylvania and an MS in Electrical Engineering and Computer Science from the University of Florida.

About Precision Therapeutics

Precision Therapeutics is a diagnostics services company dedicated to providing physicians and patients with actionable clinical information to personalize cancer treatments. Precision's ChemoFx(R) test measures an individual patient's tumor response to a range of therapeutic alternatives under consideration by a physician.

For more information, please visit

About Ernst & Young's Entrepreneur Of The Year

Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Ernst & Young's Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs. The award makes a difference through the unique way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Ernst & Young Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

For more information, please visit

SOURCE Precision Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Applied Precision Announces Sale of Life Sciences Business Unit to Senior Management and Telegraph Hill Partners
2. Precision Therapeutics Adds 8 Million Covered Lives Under Contract
3. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
4. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
5. Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order
6. New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput
7. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
8. Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years
9. 2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set
10. Jerry Steffl Joins Prime Therapeutics as Vice President, Government Affairs
11. Fischman receives Pharmacology/Therapeutics/Toxicology Research Award
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: